ANTI-NUCLEAR ANTIBODY TESTING MARKET ANALYSIS

Anti-nuclear Antibody Testing MarketSize and Trends

An exponential rise in the demand for antinuclear antibody testing has been witnessed due to increase in prevalence of autoimmune disorders such as SLE and rheumatoid arthritis, which is expected to drive the market growth over the forecast period. For instance, the U.S. Centers for Disease Control and Prevention (CDC) estimated that around 54.4 million adults suffered from arthritis in the U.S. in 2017. In 2017, the Arthritis foundation of U.S estimated a rise in the number of cases of diagnosed arthritis in the U.S. by 49% over the next 20-25 years. In addition, the Lupus Foundation of America estimated that about 5 million people around the world suffered from SLE in 2017, which further indicated that the incidence rate of lupus is 16,000 new cases per year.    

Moreover, government healthcare insurance, increase in autoimmune disorders awareness programs, and reimbursement policies drive the market growth of anti-nuclear antibody testing. For instance, the World Lupus Federation (WLF) is a union of around 250 lupus organizations in 75 countries in six continents with the aim of providing assistance to patients suffering from Lupus. WLF helps to raise awareness about Lupus amongst public and also provide access to better healthcare for patients suffering from Lupus.

Technological advancements and increase in investments in R&D for development of novel products or methodology further propel the market growth of antinuclear antibody testing. For instance, in2019, European League against Rheumatism (EULAR) and the American college of Rheumatology established a classification criterion for systemic lupus erythematosus (SLE), which suggested that the immunofluorescence testing on solid-phase anti-nuclear antibody screening immunoassay and HEp-2 cells with equal performance was highly preferred.